Evidence map›Paper›PMID 36755223›Full record

ArticleBMC cancer2023

LncRNA ANRIL promotes HR repair through regulating PARP1 expression by sponging miR-7-5p in lung cancer.

Zhipeng Du, Fangxiao Zhang, Lei Liu, Hui Shen, Tingting Liu, Jing Jin, Nanxi Yu, Zhijie Wan, Hang Wang, Xuguang Hu and 2 more

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Prognostic significance ofTranslational cancer research · 2025
    Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Plants (Basel, Switzerland) · 2024
    Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Zhipeng Du *School of Public Health and Management, Wenzhou Medical University, University Town, Wenzhou, Zhejiang, P. R. China.
Fangxiao Zhang *School of Public Health and Management, Wenzhou Medical University, University Town, Wenzhou, Zhejiang, P. R. China.
Lei Liu *Department of Oncology, General Hospital of Central Theater Command of Chinese People's Liberation Army, Wuhan, Hubei, P. R. China.
Hui ShenDepartment of Radiation Medicine, Faculty of Naval Medicine, Naval Medical University, Shanghai, P. R. China.
Tingting LiuDepartment of Radiation Medicine, Faculty of Naval Medicine, Naval Medical University, Shanghai, P. R. China.
Jing JinDepartment of Occupational and Environment Health, Xiangya School of Public Health, Central South University, Changsha, Hunan, P. R. China.
Nanxi YuSchool of Public Health and Management, Wenzhou Medical University, University Town, Wenzhou, Zhejiang, P. R. China.
Zhijie WanDepartment of Radiation Medicine, Faculty of Naval Medicine, Naval Medical University, Shanghai, P. R. China.
Hang WangDepartment of Radiation Medicine, Faculty of Naval Medicine, Naval Medical University, Shanghai, P. R. China.
Xuguang HuDepartment of Gastrointestinal Surgery, Changhai Hospital, Shanghai, P. R. China. xuguanghu@gmail.com.
Yuanyuan ChenDepartment of Radiation Medicine, Faculty of Naval Medicine, Naval Medical University, Shanghai, P. R. China. yychen1994@163.com.
Jianming CaiSchool of Public Health and Management, Wenzhou Medical University, University Town, Wenzhou, Zhejiang, P. R. China. cjm882003@163.com.
Wenzhou Medical University · CNCentral South University · CNChinese People's Liberation Army · CNNaval University of Engineering · CNSecond Military Medical University · CN

Funding

National Natural Science Foundation of China No. 81972968, No. 11635014, No. 82003387Project of South Zhejiang Institute of Radiation Medicine and Nuclear Technology No.ZFY-2021-002
6 · The paper itself

Abstract

backgroundRadiotherapy is an important treatment for lung cancer, mainly by triggering DNA double-strand breaks to induce cell death. Blocking DNA damage repair can increase the radiosensitivity of tumor cells. Recent studies have identified long noncoding RNAs as key regulators in DNA damage repair. The lncRNA ANRIL was previously shown to be involved in homologous recombination (HR) repair, but its specific mechanism has not been fully elucidated.

methodsThe downstream interacting miRNAs of ANRIL were predicted according to miRanda software. Fluorescence quantitative PCR was used to detect the expression levels of ANRIL and candidate miRNAs. Clone formation experiment and cell viability assays detect cell viability after ionizing radiation. Apoptosis assay was used to detect the apoptosis of cells after 8 h of ionizing radiation. Western blot analysis and immunofluorescence assays verified the protein expression levels of the downstream target molecule PARP1 of miR-7-5p and key molecules in the HR pathway. Fluorescent reporter gene experiments were used to verify the interaction between ANRIL and miR-7-5p and between miR-7-5p and PARP1.

resultsBioinformatics analysis and qPCR validation suggested that miR-7-5p might be a downstream molecule of ANRIL. The expression of miR-7-5p was up-regulated after knockdown of ANRIL, and the expression of miR-7-5p was down-regulated after overexpression of ANRIL. Meanwhile, there was a negative correlation between ANRIL and miR-7-5p expression changes before and after ionizing radiation. The luciferase reporter gene assay confirmed the existence of ANRIL binding site with miR-7-5p, and found that transfection of miR-7-5p inhibitor can reduce the radiation sensitivity of ANRIL-KD cells. A downstream target molecule of miR-7-5p related to HR repair, PARP1, was screened through website prediction. Subsequently, it was confirmed by Western blot and luciferase reporter assays that miR-7-5p could down-regulate the expression of PARP1, and there was a miR-7-5p binding site on the 3'UTR of PARP1 mRNA. This suggests that ANRIL may act as a competitive endogenous RNA to bind miR-7-5p and upregulate the expression of PARP1. Western blot and immunofluorescence staining were used to detect the expression changes of HR repair factors in ANRIL-KD cells after ionizing radiation, and it was found that knockdown of ANRIL can inhibit the expression of PARP1, BRCA1 and Rad51, hinder radiation-induced HR repair, and eventually result in resensitizing ANRIL-KD cells to ionizing radiation.

conclusionsOur findings provide evidence that ANRIL targets the miR-7-5p/PARP1 axis to exert its regulatory effect on HR repair, suggesting that altering ANRIL expression may be a promising strategy to overcome radiation resistance.

Indexed as

Lung NeoplasmsMicroRNAsRNA, Long NoncodingCell Line, TumorCell ProliferationDNA RepairGene Expression Regulation, NeoplasticHumansPoly (ADP-Ribose) Polymerase-1Recombinational DNA RepairCDKN2B antisense RNA, humanMicroRNAsMIRN7-1 microRNA, humanPARP1 protein, humanPoly (ADP-Ribose) Polymerase-1RNA, Long NoncodingANRILHomologous recombination repairLung cancermiR-7-5pPARP1Radiation resistance

Identifiers

PMID36755223
PMCPMC9906921
OpenAlexW4319598112

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.